BioNTech and Genentech terminated a phase 2 trial of their personalized mRNA cancer vaccine, according to reporting that followed Merck and Moderna’s phase 3 success in a different personalized cancer-vaccine context. BioNTech described the decision as a move away from continued study shortly after outcomes influenced internal strategy. The discontinuation highlights the difficulty of translating individualized mRNA approaches into consistent overall survival or durable benefit signals across tumor types and study designs. The decision also comes amid heightened competitive scrutiny as investors and partners compare read-throughs from other personalized vaccine programs. Near-term, the key industry implication is that personalized vaccine platforms will likely require more rigorous target selection, trial design refinement, and endpoint clarity to sustain development momentum.